Long-term axial elongation in myopic children wearing DIMS spectacle lenses: an 8-to-10-year observational study Authors: Tsz Wing Leung, Han Yu Zhang, Kin Ho Chan, Paul H Lee, Kenneth Ka King Liu, Yee Mui Kwok, Ka Mei To, Natalia Vlasak, Carly Siu-yin Lam Published: 2026 ABSTRACT AbstractBackground/AimTo evaluate the long-term effectiveness of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in a long-term observational follow-up (>8 years) of an original randomised clinical trial cohort transitioning into late adolescence.MethodsThis observational post-trial study included 60 young adults (mean age: 19.97±1.64 years) from the original DIMS trial (baseline age: 8–13 years) followed for an average of 9.4±0.3 years. Longitudinal changes in spherical equivalent refraction (SER) and axial length (AL) were analysed using linear mixed-effects models (LMM) to compare rates of change during DIMS versus single vision (SV) wear periods. LMM predictions were benchmarked against an external meta-analysis for untreated Asian children.ResultsThe LMM revealed a significant treatment effect for DIMS on axial elongation (p=0.003), with a predicted 65% cumulative reduction versus modelled SV wear (0.44±0.11 mm vs 1.27±0.11 mm). Conversely, the LMM found no statistically significant effect on SER progression (p=0.83), despite predicting a large, clinically meaningful cumulative difference (DIMS: –0.57±0.32 D vs SV: –2.17±0.37 D). The LMM-predicted elongation for continuous DIMS wear was 76% lower than the external untreated norm.ConclusionsDIMS spectacle lens provides sustained slowing of axial elongation through late adolescence, yielding substantial benefits compared with modelled SV wear and external norms. However, this significant biological effect did not translate to a statistically significant refractive error effect in the LMM, possibly due to the low signal-to-noise ratio inherent to long-term autorefraction measurements and the lack of a contemporaneous, untreated single-vision control group. Further research should address this paradox between significant AL control and non-significant SER outcomes in long-term studies.Keywords: Child health (paediatrics) WHAT IS ALREADY KNOWN ON THIS TOPIC While Defocus Incorporated Multiple Segments (DIMS) spectacle lenses effectively slow myopia progression over 2 to 6 years, their sustained efficacy through late adolescence and over nearly a decade of wear remained unknown. While Defocus Incorporated Multiple Segments (DIMS) spectacle lenses effectively slow myopia progression over 2 to 6 years, their sustained efficacy through late adolescence and over nearly a decade of wear remained unknown. WHAT THIS STUDY ADDS This 8-to-10-year observational study demonstrates that DIMS lenses provide a statistically significant, sustained cumulative reduction in both axial elongation (65% modelled efficacy) and myopia progression over a 9.4-year period compared with modelled single-vision wear. This 8-to-10-year observational study demonstrates that DIMS lenses provide a statistically significant, sustained cumulative reduction in both axial elongation (65% modelled efficacy) and myopia progression over a 9.4-year period compared with modelled single-vision wear. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings support the continuous clinical prescription of DIMS lenses through late adolescence for durable myopia control, while cautioning practitioners that long-term treatment success must be evaluated using cumulative metrics rather than inherently noisy visit-to-visit autorefraction changes. These findings support the continuous clinical prescription of DIMS lenses through late adolescence for durable myopia control, while cautioning practitioners that long-term treatment success must be evaluated using cumulative metrics rather than inherently noisy visit-to-visit autorefraction changes. Introduction The global prevalence of myopia has escalated dramatically over recent decades, with current projections estimating that it will affect half of the world’s population by 2050,1 2 establishing it as a significant public health concern. Beyond merely causing distance blur, myopia increases the risk for multiple sight-threatening ocular pathologies, including myopic macular degeneration, retinal detachment and glaucoma,3,5 which can lead to irreversible vision loss. Consequently, the escalating prevalence poses substantial public health and socioeconomic challenges,6 7 with estimated global productivity losses exceeding US$200 billion from uncorrected myopia and an additional US$6 billion for the management of myopic macular degeneration.6 To address this growing issue, a range of clinical interventions—including behavioural, light-based, pharmacological and optical—have been developed to slow down myopia progression. Increased outdoor time,8 repeated low-level red-light therapy,9 low-concentration atropine,10 orthokeratology,11 various multifocal contact lenses (MiSight,12 Defocus Incorporated Soft Contact (DISC)13 and DISC3.5plus)14 and novel spectacle lenses (Defocus Incorporated Multiple Segments (DIMS) lens,15 Highly Aspherical Lenslet Target lens16 and Diffusion Optics Technology lens)17 have all demonstrated notable efficacy. However, the efficacy of these interventions varies, with reported reductions in myopia progression ranging from approximately 27% to 67%, depending on the specific modality and dosage.18 19 Among those, the DIMS Technology is a pioneering spectacle lens design, engineered as one of the first to control myopia progression by imposing myopic defocus in the periphery of spectacle lenses. This is achieved through a unique dual-focus lens structure, which features a central optical zone to correct distance refractive error, surrounded by a honeycomb pattern of small, circular defocus segments that introduce +3.5 D of myopic defocus.15 This design ensures that the wearer receives both sharp foveal vision and peripheral defocus signals intended to slow down eye growth. The efficacy of the DIMS spectacle lens was initially established in a 2-year, double-masked randomised controlled trial (RCT), which demonstrated that DIMS spectacle lens wear significantly slowed down myopia progression by 0.44 D and axial elongation by 0.34 mm compared with single vision (SV) spectacle lenses.15 A subsequent 3-year follow-up study affirmed this sustained effect, showing that myopia control was maintained in the original treatment group.20 Furthermore, children from the original control group who were switched to DIMS wear showed a significant subsequent reduction in myopia progression and axial elongation.20 A 6-year follow-up further confirmed the long-term efficacy for those who continued wearing the lenses and revealed no rebound effect in those who ceased wear.21 This observational, post-trial follow-up, extending beyond 8 years and the longest to date for this cohort, evaluates the sustained effects of DIMS spectacle lens wear as these children transition into late adolescence (17–23 years). The primary objective is to analyse the longitudinal changes in axial length (AL) and spherical equivalent refraction (SER) using linear mixed-effects modelling (LMM). This unique, long-term perspective allows for an assessment of the cumulative treatment effect over nearly a decade and provides novel insights into the efficacy of DIMS wear in an older adolescent cohort nearing refractive stability. Method Study design and participants This observational, post-trial follow-up study invited all children who successfully completed the initial 2-year RCT15 and the subsequent 3-year20 and 6-year21 follow-up studies. The final follow-up visit occurred more than 8 years after the original trial’s baseline. The original RCT enrolled children aged 8 to 13 years with myopia from –1.00 to –5.00 D (SER), astigmatism and anisometropia of 1.50 D or less, and no history of ocular disease or myopia control interventions.15 In the initial 2-year RCT, participants were randomised to wear either DIMS spectacle lenses or SV spectacle lenses.15 Due to ethical considerations, the SV group was switched to DIMS spectacle lenses at the beginning of the third year (months 24 to 42). At the 6-year follow-up, participants were categorised into four groups based on their spectacle-wear history21: Group 1 (n=36): Original DIMS group participants who continued with DIMS spectacle lenses. Group 1 (n=36): Original DIMS group participants who continued with DIMS spectacle lenses. Group 2 (n=14): Original DIMS group participants who switched to SV spectacle lenses after 3.5 years. Group 2 (n=14): Original DIMS group participants who switched to SV spectacle lenses after 3.5 years. Group 3 (n=22): Original control (SV) group participants who switched to DIMS spectacle lenses in the 3-year follow-up study and continued with them. Group 3 (n=22): Original control (SV) group participants who switched to DIMS spectacle lenses in the 3-year follow-up study and continued with them. Group 4 (n=18): Original control (SV) group participants who switched to DIMS spectacle lenses in the 3-year follow-up study but later reverted to SV spectacle lenses. Group 4 (n=18): Original control (SV) group participants who switched to DIMS spectacle lenses in the 3-year follow-up study but later reverted to SV spectacle lenses. Following the conclusion of the 6-year follow-up, participants were informed that the formal study period had ended. They were advised that no further complimentary DIMS spectacle lenses would be provided and that they were free to choose any form of visual correction. For the current observational study, all participants who had completed the 6-year visit were invited to return for a final examination, which was scheduled at least 2 years after their 6-year visit (ie, 8+ years from the original baseline). Because successful completion of the 6-year study required complete follow-up records from the preceding trials, all invited participants had inherently attended all prior scheduled study visits. The study was conducted at the Centre for Myopia Research at The Hong Kong Polytechnic University (same as the previous RCTs). Patient and public involvement Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research. The study was a long-term observational follow-up of a previously established clinical trial cohort, and the research questions and outcome measures were determined by clinical standards for myopia progression. Study procedures and outcome measures A comprehensive eye examination was performed at the final follow-up visit by registered optometrists. Participants were asked to self-report the types of spectacle lenses or other myopia interventions, if any, they had used since their last visit. The primary outcome measures, cycloplegic SER and AL, were collected using the same protocol as the original RCT.15 Cycloplegia was induced with one drop of proparacaine 0.4% followed by one to two drops of 1% cyclopentolate HCl. Specifically, a single drop of cyclopentolate was instilled initially, and cycloplegia was subsequently evaluated using the push-up method. An additional drop was administered only if the residual amplitude of accommodation remained >2 D. Cycloplegic autorefraction was measured using a Shin-Nippon NVision-K5001 open-field autorefractor (Ajinomoto Trading, Japan) and AL was measured using an IOL Master (Carl Zeiss Meditec, Germany). Statistical analysis Data from the right eyes were used for analysis, and results are presented as mean±SD unless otherwise stated. All statistical analyses were conducted using Python (V.3.11.5) with the scipy (V.1.14.0) and statsmodels (V.0.14.2) libraries. A p<0.05 was considered statistically significant. To determine the longitudinal effects of DIMS spectacle lens wear, we employed a LMM. This approach was chosen as it is well-suited for longitudinal data, which is inherently correlated (multiple, non-independent measurements from the same individual) and often unbalanced (eg, varied follow-up intervals between visits). The annualised rates of change in AL and SER between consecutive visits served as the outcome variables, calculated by dividing the difference in AL or SER by the time interval. The model’s fixed effects were the mean age at the mid-point of the interval, the spectacle lens wear status (DIMS vs SV), and their interaction. The natural logarithm of age, ln(Age), was used instead of raw age to account for the non-linear slowing of progression over time. A random intercept was included for each individual to account for this non-independent, correlated data. The overall myopia control efficacy was estimated by integrating the final LMM over time, starting from the baseline age of each individual. Because standard analytical CIs cannot be directly applied to this integrated trajectory, 95% CIs for the cumulative predictions were derived using parametric bootstrapping to account for the joint uncertainty and covariance of the fixed effects. Specifically, 10 000 Monte Carlo simulations were drawn from the LMM’s estimated covariance matrix to calculate the expected total change under two hypothetical scenarios (continuous DIMS wear and continuous SV wear). The cumulative modelled efficacy was defined as the mean difference between the two predicted outcomes, divided by the mean predicted outcome for the SV scenario. To contextualise the findings, progression rates within our cohort were compared descriptively to published normative data for Asian populations from a recent meta-analysis.22 Results Of the 90 participants who completed the 6-year follow-up study,21 63 (70%) participated in this final follow-up. This represents a 39% retention rate from the original 2-year RCT baseline cohort (n=160),15 and a 49% retention rate from the 3-year follow-up study (n=128).20 Among the 27 participants from the 6-year cohort who did not return, the specific reasons for non-participation were emigration (n=15), declining to participate (n=9) and scheduling conflicts (n=3). From this cohort, three participants were excluded from the final analysis due to the use of other myopia control interventions (n=2) or incomplete lenses wearing data (n=1), leaving 60 participants for the analysis. The final sample sizes were 27, 7, 14, and 12 in groups 1, 2, 3 and 4, respectively. At baseline, there were no significant differences in age, gender, SER or AL across the four groups (table 1; Kruskal-Wallis tests, χ2(3)≤4.71, p≥0.20). Although the initial analysis indicated a significant difference in follow-up duration across groups (χ2(3)=8.29, p=0.04), subsequent post hoc testing revealed no significant pairwise differences (Dwass-Steel-Critchlow-Fligner tests, W≤3.10, p≥0.13). Table 1Demographic informationParametersDIMS groupsKruskal-Wallis Between-group comparisonsGroup 1Group 2Group 3Group 4AllGender (male:female)14:136:16:86:632:28χ2=23.58,p=0.31Baseline age (years)10.37±1.65(8.02 to 13.77)10.27±1.03(8.53 to 11.69)10.80±1.54(8.46 to 13.10)10.75±2.13(8.09 to 13.96)10.54±1.65(8.02 to 13.96)χ2=20.64,p=0.89Final age (years)19.73±1.62(17.56 to 23.47)19.61±1.05(17.91 to 21.21)20.34±1.50(18.09 to 22.52)20.30±2.11(17.84 to 23.22)19.97±1.64(17.56 to 23.47)χ2=21.31,p=0.73Follow-up duration (years)9.37±0.19(8.96 to 9.70)9.35±0.20(8.99 to 9.53)9.54±0.30(9.03 to 9.92)9.54±0.33(8.84 to 9.98)9.44±0.26(8.84 to 9.98)χ2=28.29,p=0.04Baseline SER (D)−3.02±0.87(−4.56 to −1.56)−2.97±1.47(−5.06 to −1.50)−2.66±0.80(−4.68 to −1.62)−2.55±1.36(−5.30 to −1.00)−2.83±1.04(−5.30 to −1.00)χ2=23.08,p=0.38Baseline axial length (mm)24.68±0.77(23.44 to 26.29)24.93±0.96(23.08 to 26.32)24.77±0.65(23.35 to 25.55)24.26±0.93(23.04 to 26.30)24.65±0.81(23.04 to 26.32)χ2=24.71,p=0.20Numerical data are presented as mean±SD (range).DIMS, Defocus Incorporated Multiple Segments; SER, spherical equivalent refraction. Demographic information Numerical data are presented as mean±SD (range). DIMS, Defocus Incorporated Multiple Segments; SER, spherical equivalent refraction. LMMs: effects of DIMS wear on myopia progression and axial elongation The primary analysis using LMMs revealed the longitudinal effects of age and DIMS spectacle lens wear on axial elongation and myopia progression. For axial elongation, the rate of change significantly slowed with increasing ln(Age) (p<0.001) and was significantly slower during periods of DIMS spectacle lens wear compared with SV spectacle lens wear (p=0.003). A significant interaction was found between ln(Age) and DIMS wear (p=0.02), indicating that the reduction in axial growth with DIMS spectacle lenses was more pronounced at younger ages (specifically, before age 18) (figure 1, table 2). To quantify the cumulative effect for our specific cohort (a mean baseline age of 10.5 years over a 9.4-year follow-up period), we used parametric bootstrapping with 10 000 simulations of the LMM parameters to predict the total axial elongation. For each simulation, the predicted trajectory was integrated for all 60 participants based on their individual baseline ages under two hypothetical scenarios, and the cohort averages were calculated. The estimated total axial elongation was 0.44±0.11 mm (95% CI 0.24 to 0.65 mm) for a hypothetical continuous DIMS wearer, compared with 1.27±0.11 mm (95% CI 1.04 to 1.50 mm) for a hypothetical continuous SV wearer, yielding a cumulative modelled efficacy of 65% in slowing axial elongation. Linear mixed-effects model (LMM) of axial elongation rate. Each dot represents the annualised rate of axial elongation (mm/year) for a single participant between two consecutive visits, plotted against their mean age during that interval. The solid lines show the LMM-predicted rate of change as a function of age, back-transformed from ln(Age) to the linear age scale, for periods of DIMS wear (red) and SV wear (blue). Shaded regions represent the 95% CIs for the model’s predictions. The black dashed line shows the predicted normative progression for an untreated Asian cohort for comparison, based on the meta-regression by Brennan et al.22 DIMS, Defocus Incorporated Multiple Segments; SV, single vision. Table 2Linear mixed model for the prediction of the rate of axial elongationParametersEstimates±SE95% CI (lower, upper)P valueIntercept1.065±0.112(0.846 to 1.284)<0.001ln(Age)−0.344±0.042(−0.427 to −0.261)<0.001DIMS−0.460±0.156(−0.765 to −0.156)0.003DIMS*ln(Age)0.138±0.059(0.021 to 0.254)0.020DIMS, Defocus Incorporated Multiple Segments. Linear mixed model for the prediction of the rate of axial elongation DIMS, Defocus Incorporated Multiple Segments. For myopia progression, the rate of change in SER also slowed significantly with ln(Age) (p=0.004). However, the model found no statistically significant main effect for DIMS treatment (p=0.94) and no significant interaction with age (p=0.83) on SER progression (figure 2, table 3). Using the same parametric bootstrapping approach, the model estimated the total myopia progression over the 9.4-year study period to be –0.57±0.32 D (95% CI –1.20 to 0.06 D) for a hypothetical continuous DIMS wearer versus—2.17±0.37 D (95% CI –2.89 to –1.44 D) for an SV wearer. Because these 95% CIs do not overlap, this demonstrates that, specifically when integrating the trajectories from the participants’ individual baseline ages over the 9.4-year follow-up, the cumulative reduction in myopia progression remains statistically significant. Linear mixed-effects model (LMM) of myopia progression rate. Each dot represents the annualised rate of myopia progression (D/year) for a single participant between two consecutive visits, plotted against their mean age during that interval. The solid lines show the LMM-predicted rate of change as a function of age, back-transformed from ln(Age) to the linear age scale, for periods of DIMS wear (red) and SV wear (blue). Shaded regions represent the 95% CIs for the model’s predictions. DIMS, Defocus Incorporated Multiple Segments; SV, single vision. Table 3Linear mixed model for the prediction of the rate of myopia progressionParametersEstimates±SE95% CI (lower, upper)P valueIntercept−1.470±0.415(−2.283 to −0.656)<0.001ln(Age)0.459±0.159(0.147 to 0.770)0.004DIMS0.045±0.561(−1.054 to 1.145)0.936DIMS*ln(Age)0.046±0.213(−0.378 to 0.470)0.831DIMS, Defocus Incorporated Multiple Segments. Linear mixed model for the prediction of the rate of myopia progression DIMS, Defocus Incorporated Multiple Segments. Discussion This follow-up observational study represents the longest post-trial investigations into the efficacy of DIMS spectacle lenses for myopia control. Our cohort, followed from childhood (8–13 years) into late adolescence (17–23 years), provides critical insights into the long-term sustained effects of this myopia control intervention. The principal finding from our primary longitudinal analysis was a significant and sustained treatment effect on axial elongation (figure 1). The LMM predicted a cumulative 65% reduction in axial elongation over 9.4 years for a hypothetical continuous DIMS wearer compared with the prediction of the model for SV wear. This effect was significantly moderated by age, with the treatment being more potent in children younger than 18 years, which aligns with the established principle that myopia progression is more rapid at a younger age.23 This finding of sustained AL control was further supported by a direct comparison to an age-matched historical control group, which demonstrated a significantly slower rate of axial elongation among DIMS wearers. To contextualise this effect against an external benchmark, we used the prediction equation from a previous meta-regression.22 This model accounts for the influence of both baseline age and race on axial elongation. By inputting our cohort’s specific parameters, that is, an Asian demographic, a mean baseline age of 10.5 years and a follow-up duration of 9.4 years, the model predicts a cumulative axial elongation of 1.85 mm for an untreated cohort. While comparing a specific regional cohort to a generalised Asian model carries certain inherent limitations, the initial demographics and baseline measures are sufficiently comparable to provide a contextual baseline. This predicted untreated elongation (1.85 mm) is substantially greater than our LMM prediction of 0.44 mm for a hypothetical continuous DIMS wearer. This comparison suggests that continuous DIMS wear resulted in an approximate cumulative modelled efficacy of 76% relative to the untreated Asian norm. A perhaps unexpected finding of this long-term study was the insignificant SER finding. In contrast to the significant AL finding, the LMM did not find a statistically significant effect for SER. However, parametric bootstrapping, which integrated trajectories from participants’ individual baseline ages, revealed a substantial and clinically meaningful difference in cumulative myopia progression over the 9.4-year period (DIMS: –0.57±0.32 D vs SV: –2.17±0.37 D, with non-overlapping 95% CIs). This apparent paradox—a large cumulative difference that is not statistically significant at the instantaneous rate level—is explained by two primary hypotheses. First, the LMM’s variance analysis revealed a critically low signal-to-noise ratio (SNR) for the SER data. The intraclass correlation coefficient for the SER model was 0.003 (0.3%), indicating that 99.7% of the variance was unexplained residual ‘noise’ rather than stable, between-subject differences. This could be due to the statistical consequence of the measurement methodology. The ‘noise’ from Shin-Nippon NVision-K5001 autorefractor (repeatability ±0.50 D; step size 0.125 D)24 is substantial relative to the annual ‘signal’ being measured (annual myopia progression, DIMS: –0.10 D/year; SV: –0.24 D/year for SV). This low SNR and high residual noise inflated the standard errors of the fixed effects (table 3, DIMS coefficient: 0.045±0.561), rendering the model statistically unable to discern a true effect from the noise. Second, this high noise scenario was compounded by a small ‘signal,’ as the SV wear data in our LMM does not represent a true, untreated control. A comparison with the external meta-analysis reveals that our model-predicted axial elongation for SV wear (1.39 mm) is substantially lower than the predicted Asian norm (1.85 mm).22 Given that all participants had a history of DIMS spectacle lens wear, it is probable that a persistent treatment effect confounded the SV-wear periods, artificially shrinking the true ‘signal’ (the DIMS vs SV difference). This finding is also consistent with our previous 6-year follow-up, which found no evidence of a rebound effect after DIMS cessation.21 Consequently, the SV wear data does not appear to represent an untreated state but rather a confounded control, likely reflecting a combination of prior cumulative benefits and a simple cessation of effect. The high residual variance (low SNR) and a compromised treatment signal (a confounded control) might explain the non-significant findings in the SER model. However, this hypothesis cannot be definitively tested within the constraints of this observational study, which lacks a contemporaneous untreated control group. While this study presents, to our knowledge, the longest follow-up observation of this myopia control intervention, its limitations must be acknowledged. First, the observational design, while ethically appropriate given the known efficacy of DIMS, lacks a contemporaneous, untreated control group. This limited our ability to predict the true treatment effect, as all participants, even the SV-wear data, had prior DIMS exposure. Second, as is common in such long-term longitudinal studies, significant sample size reduction from the original RCT has limited our statistical power, particularly for subgroup analyses such as the RPR cohort. Furthermore, this attrition introduces the potential for survivor bias. The participants who chose to remain in the study for over 8 years may represent a self-selected group who experienced favourable myopia control, excellent tolerance and high satisfaction with the DIMS lenses, which could potentially inflate the long-term efficacy estimates compared with the broader original cohort. Finally, the follow-up durations were variable. Thus, instead of direct comparisons between visits, our primary analysis used LMMs focused on the rate of change, a method specifically chosen to handle such data. In conclusion, this long-term follow-up study provides robust evidence that the effects of DIMS wear on slowing axial elongation are sustained through late adolescence. The cumulative benefit was substantial, with continuous DIMS wear predicting an approximate 76% reduction in axial elongation compared with untreated normative data from a recent meta-analysis. This finding provides strong evidence for the long-term biological effectiveness of DIMS as a non-invasive myopia control strategy. However, this biological effect did not translate to a statistically significant effect on refractive error in the LMM. Further research is needed to understand this AL and SER paradox in long-term observational studies. Acknowledgements This project was funded by the HOYA Holdings NV (P0050726) and was supported by the InnoHK initiative of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government. We thank the sponsor for their assistance in reviewing the final manuscript. Footnotes Funding: This project was supported by the HOYA Holdings NV (P0050726). Data availability free text: Deidentified participant data that underlie the results reported in this article, along with the statistical analysis code, are available on reasonable request to the corresponding author Tsz Wing LEUNG. Due to the nature of this funded research, data sharing is subject to review and approval from the study funder and requires the execution of a formal data sharing agreement to ensure the ongoing protection of human subjects and proprietary data. Patient consent for publication: Consent obtained from parent(s)/guardian(s). Ethics approval: All procedures adhered to the tenets of the Declaration of Helsinki and were approved by the Human Subjects Ethics Sub-committee of The Hong Kong Polytechnic University (HSEARS20240108001). Informed consent was obtained from parents or guardians and assent was obtained from the children. Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement Data are available on reasonable request. References Associated Data Data Availability Statement Data are available on reasonable request.